Plasma levels of pentraxin-3, an acute phase protein, are increased during sickle cell painful crisis

Blood Cells, Molecules, and Diseases

Volumn 46, Issue 3, 2011, Pages 189-194

  Nur, Erfan ^a,b   van Beers, Eduard J ^b   Martina, Shuena ^b   Cuccovillo, Ivan ^c   Otten, Hans Martin ^a   Schnog, John John B ^a,d   Meijers, Joost C M ^b   Mantovani, Alberto ^c   Brandjes, Dees P ^a   Bottazzi, Barbara ^c   Biemond, Bart J ^b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d Sint Elisabeth Hospital   (Netherlands)

Author keywords

Ischemia; Painful crisis; Pentraxin 3; Sickle cell disease

Indexed keywords

ANTITHROMBIN; C REACTIVE PROTEIN; PENTRAXIN 3; PROTHROMBIN; THROMBIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDOTHELIUM; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; LENGTH OF STAY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SICKLE CELL CRISIS; UPREGULATION;

ADULT; ANEMIA, SICKLE CELL; C-REACTIVE PROTEIN; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; SERUM AMYLOID P-COMPONENT; THROMBOPHILIA; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 79952104125     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.10.016     Document Type: Article

References (33)

1. Schnog J.J., Lard L.R., Rojer R.A., et al. New concepts in assessing sickle cell disease severity. Am. J. Hematol. 1998, 58:61-66.
2. Serjeant G.R. The emerging understanding of sickle cell disease. Br. J. Haematol. 2001, 112:3-18.
3. Kato G.J., McGowan V., Machado R.F., et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006, 107:2279-2285.
4. Serjeant G.R., Ceulaer C.D., Lethbridge R., et al. The painful crisis of homozygous sickle cell disease: clinical features. Br. J. Haematol. 1994, 87:586-591.
5. Platt O.S., Thorington B.D., Brambilla D.J., et al. Pain in sickle cell disease. Rates and risk factors. N Engl J. Med. 1991, 325:11-16.
6. Charache S., Terrin M.L., Moore R.D., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J. Med. 1995, 332:1317-1322.
7. Frenette P.S. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr. Opin. Hematol. 2002, 9:101-106.
8. Mankad V.N., Williams J.P., Harpen M.D., et al. Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. Blood 1990, 75:274-283.
9. Mantovani A., Garlanda C., Doni A., Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J. Clin. Immunol. 2008, 28:1-13.
10. Bottazzi B., Vouret-Craviari V., Bastone A., et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J. Biol. Chem. 1997, 272:32817-32823.
11. Muller B., Peri G., Doni A., et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit. Care Med. 2001, 29:1404-1407.
12. Fazzini F., Peri G., Doni A., et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 2001, 44:2841-2850.
13. Luchetti M.M., Piccinini G., Mantovani A., et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin. Exp. Immunol. 2000, 119:196-202.
14. Peri G., Introna M., Corradi D., et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
15. Latini R., Maggioni A.P., Peri G., et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
16. Doni A., Peri G., Chieppa M., et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur. J. Immunol. 2003, 33:2886-2893.
17. Garlanda C., Bottazzi B., Bastone A., Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 2005, 23:337-366.
18. Bottazzi B., Garlanda C., Salvatori G., et al. Pentraxins as a key component of innate immunity. Curr. Opin. Immunol. 2006, 18:10-15.
19. Napoleone E., Di Santo A., Bastone A., et al. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler. Thromb. Vasc. Biol. 2002, 22:782-787.
20. Napoleone E., Di Santo A., Peri G., et al. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J. Leukoc. Biol. 2004, 76:203-209.
21. Powars D.R., Hiti A., Ramicone E., et al. Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors. Am. J. Hematol. 2002, 70:206-215.
22. Kaul D.K., Hebbel R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. Clin. Invest. 2000, 106:411-420.
23. Nath K.A., Grande J.P., Croatt A.J., et al. Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am. J. Pathol. 2005, 166:963-972.
24. Souza D.G., Soares A.C., Pinho V., et al. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am. J. Pathol. 2002, 160:1755-1765.
25. Souza D.G., Amaral F.A., Fagundes C.T., et al. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am. J. Pathol. 2009, 174:1309-1318.
26. van Beers E.J., Schaap M.C., Berckmans R.J., et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009, 94:1513-1519.
27. Singer S.T., Ataga K.I. Hypercoagulability in sickle cell disease and beta-thalassemia. Curr. Mol. Med. 2008, 8:639-645.
28. Jeney V., Balla J., Yachie A., et al. Pro-oxidant and cytotoxic effects of circulating heme. Blood 2002, 100:879-887.
29. Makis A.C., Hatzimichael E.C., Stebbing J., Bourantas K.L. C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease. Arch. Intern. Med. 2006, 166:366-368.
30. Bargoma E.M., Mitsuyoshi J.K., Larkin S.K., et al. Serum C-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome. Blood 2005, 105:3384-3385.
31. Salio M., Chimenti S., De A.N., et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008, 117:1055-1064.
32. Mauri T., Coppadoro A., Bellani G., et al. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit. Care Med. 2008, 36:2302-2308.
33. Sprong T., Peri G., Neeleman C., et al. Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock 2009, 31:28-32.